scholarly journals Dysphonia after Bevacizumab Rechallenge: A Case Report

2015 ◽  
Vol 8 (3) ◽  
pp. 423-425 ◽  
Author(s):  
Corey A. Carter ◽  
Scott Z. Caroen ◽  
Arnold L. Oronsky ◽  
Bryan T. Oronsky
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Advanced Colorectal Cancer ◽  
Vascular Endothelial ◽  
Standard Chemotherapy ◽  
Vegf Signaling ◽  
First Case ◽  
Voice Changes ◽  
Endothelial Growth Factor ◽  
Tumor Growth And Invasion

Inhibition of vascular endothelial growth factor (VEGF) signaling, an initiator of tumor angiogenesis, inhibits tumor growth and invasion. Bevacizumab, a monoclonal antibody to VEGF, in common use as an adjunct to standard chemotherapy like irinotecan in advanced colorectal cancer, also affects the normal (nontumor) vasculature. Dysphonia or voice changes have been anecdotally reported in patients that have been exposed to antiangiogenics. In this case report, we present an occurrence of severe dysphonia in a 60-year-old male with metastatic colorectal cancer after reintroduction of irinotecan and bevacizumab. To our knowledge, this is the first case of dysphonia associated with bevacizumab rechallenge.

Bevacizumab plus FOLFOX7 as first line treatment in patients with advanced colorectal cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15092-e15092
Author(s):  
M. Oukkal ◽  
F. Kara ◽  
S. Difi ◽  
D. Bouzidi ◽  
K. Bentabak ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Progressive Disease ◽  
Advanced Colorectal Cancer ◽  
Complete Response ◽  
Severe Toxicity ◽  
Vascular Endothelial ◽  
Significant Survival ◽  
Promising Treatment ◽  
Ecog Ps ◽  
Endothelial Growth Factor

e15092 Background: Bevacizumab a monoclonal antibody against vascular endothelial growth factor (VEGF) has shown in combination with chemotherapy a significant survival improvement in pts with advanced colorectal cancer (F. Kabbinavar JCO 2005 and H. Hurwitz NEJM 2004). In this study we investigated the safety and the efficacy of the addition of bevacizumab to FOLFOX7 regimen in pts with metastatic colorectal cancer. Methods: Inclusion criteria: Histological proven colorectal carcinoma, measurable disease at time of inclusion, no prior chemotherapy (adjuvant chemotherapy allowed), no CNS metastasis, no peripheral neuropathy, no other serious concomitant illness, ECOG PS ≤ 2, Urine dipstick of proteinuria <2+, adequate renal and liver function, good bone marrow reserve and informed consent. Pts received bimonthly Oxaliplatin 130 mg/m2 D1, Folinic acid 400 mg/m2 D1, Fluorouracil 2400 mg/m2 46 hours continuous infusion and Bevacizumab 5mg/kg D3 Results: From April 2005 to June 2007, 47 pts (M/F = 28/19, colon/rectum = 28/19) were enrolled in the study. Median age is 52,7 years old (32–74). They received 452 cycles, median=7 range (1–18). All pts were evaluable for toxicity and survival and 46 for responses. Complete response (CR) was achieved in 3 pts (6.6%), partial response (PR) in 28 pts (60.8%), stable disease in 4 pts (8.7%) and progressive disease in 11 pts (24%). The overall response rate (ORR=CR+PR) is 67.3%. Severe toxicity (CTC/NCI ¾ Grade) related to chemotherapy was neuropathy 5.3%, neutropenia 8.4%, anaemia 3.3%, thrombocytopenia 1.8%, vomiting 8.2%, diarrhoea 2.9%, stomatis 4.9% and allergy 0.7%. Toxicity related to Bevacizumab was bleeding CTCNCI grade 1 and 2 in 40.8%, hypertension grade 1 qnd 2 in 3.7% qnd grqde 3 in 0.2. proteinuria grade and 2 in 13.7%. 1 case of phlebitis and 1 case of Bevacizumab allergy Conclusions: Bevacizumab and FOLFOX7 combination is a promising treatment with high efficacy and safety profile for pts with advanced colorectal cancer No significant financial relationships to disclose.

scholarly journals Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients

2019 ◽  
Vol 65 (2) ◽  
pp. 177-182
Author(s):  
Kong Ying ◽  
Yang Chong ◽  
Wang Wei ◽  
Dong Bing ◽  
Su Yanyan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
Total Efficiency ◽  
Therapeutic Effects ◽  
Vascular Endothelial ◽  
Vegf Expression ◽  
Before And After ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

SUMMARY OBJECTIVE: To explore the effect of FOLFOX6 chemotherapy on serum vascular endothelial growth factor (VEGF) expression in advanced colorectal cancer patients. METHODS: A retrospective analysis of 81 patients with advanced colorectal cancer who visited our hospital from March 2014 to February 2016 was performed. All the patients were treated with FOLFOX6 chemotherapy. On day 1, patients received oxaliplatin 100 mg/m2 ivgtt (2h), calcium folinate 200 mg/m2 ivgtt (2h), 5 fluorouracil 400 mg/m2 iv bolus and 5 fluorouracil 2500 mg/m2 ivgtt (5h). The treatment course was 2 weeks, and 4 treatment courses were required. The changes in the levels of VEGF and CRP and quality of life before and after 4 courses of chemotherapy were observed and therapeutic effects and adverse reactions after chemotherapy were evaluated. RESULTS: After treatment, the total efficiency of chemotherapy was 82.72% (67/81) with 24 cases in complete remission, 25 cases in partial response, 18 cases in stable disease and 14 cases in progressive disease. The levels of CRP and VEGF after the treatment were significantly lower than those before treatment (5.69±0.77) mg/L vs. (7.99±1.36) mg/L; (443.26±21.55) pg/mL vs. (542.83±20.44) pg/mL] (P<0.05). The KPS grade after treatment was significantly higher than that before treatment (57.84±4.6) point vs. (50.99±3.73) point] (P<0.05). Among them, 3 cases developed a rash, 5 cases experienced hair loss, and 9 cases developed nausea and vomiting. CONCLUSION: FOLFOX6 chemotherapy can decrease serum VEGF expression in patients with advanced colorectal cancer and enhance the curative effect with high safety, which is good for the improvement of patients' survival.

Sign in / Sign up

Export Citation Format

Share Document